Literature DB >> 7993908

Kinetic mechanism for the interaction of Hirulog with thrombin.

M A Parry1, J M Maraganore, S R Stone.   

Abstract

Hirulog (D-FPRPGGGGDGDFEEIPEEYL) is a bivalent inhibitor of thrombin consisting of a moiety (D-FPRP) that binds to the active-site cleft and a hirudin-like C-terminal region (DGDFEEIPEEYL) that binds to the positively charged surface groove of thrombin known as the anion-binding exosite. The formation of the thrombin-Hirulog complex was studied using steady-state and rapid kinetics at 37 degrees C. The inhibition constant for Hirulog was found to be 1.9 nM. Hirulog was slowly degraded by thrombin with a kcat value of 0.01 s-1. The formation of the complex resulted in an enhancement of 44% in the intrinsic fluorescence of thrombin. The kinetics of the increase in thrombin fluorescence were described by a double-exponential decay. The dependence of the rate constant for the fast phase on the concentration of Hirulog could be described by the Michaelis-Menten equation with Km and kmax values of 0.75 +/- 0.12 microM and 325 +/- 17 s-1. The data were consistent with a mechanism in which the C-terminal region of Hirulog binds to the anion-binding exosite with a dissociation constant of 0.75 microM in the first step, followed by two intramolecular steps with rate constants of about 300 and 30 s-1. A C-terminal fragment of hirudin was found to compete in the first step confirming that this process corresponded to the binding of the hirudin-like C-terminus of Hirulog to the anion-binding exosite.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7993908     DOI: 10.1021/bi00253a020

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

Review 1.  Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention.

Authors:  Marit D Moen; Gillian M Keating; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Protease-resistant peptide ligands from a knottin scaffold library.

Authors:  Jennifer A Getz; Jeffrey J Rice; Patrick S Daugherty
Journal:  ACS Chem Biol       Date:  2011-06-16       Impact factor: 5.100

Review 3.  Direct thrombin inhibitors: pharmacology and application in intensive care medicine.

Authors:  Eva Schaden; Sibylle A Kozek-Langenecker
Journal:  Intensive Care Med       Date:  2010-04-28       Impact factor: 17.440

Review 4.  Bivalirudin: a review of its potential place in the management of acute coronary syndromes.

Authors:  Christopher I Carswell; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1).

Authors:  Christopher J Farady; Jeonghoon Sun; Molly R Darragh; Susan M Miller; Charles S Craik
Journal:  J Mol Biol       Date:  2007-04-04       Impact factor: 5.469

Review 6.  [Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia].

Authors:  S A Kozek-Langenecker
Journal:  Anaesthesist       Date:  2008-06       Impact factor: 1.041

Review 7.  Bivalirudin in percutaneous coronary intervention.

Authors:  Sam J Lehman; Derek P Chew
Journal:  Vasc Health Risk Manag       Date:  2006

8.  Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin.

Authors:  Asif Iqbal; Mauricio Barbugiani Goldfeder; Rafael Marques-Porto; Huma Asif; Jean Gabriel de Souza; Fernanda Faria; Ana Marisa Chudzinski-Tavassi
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

Review 9.  New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?

Authors:  María Asunción Esteve-Pastor; Diana Hernández-Romero; Mariano Valdés; Francisco Marín
Journal:  Molecules       Date:  2016-02-27       Impact factor: 4.411

Review 10.  Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.

Authors:  Ravi K Ramana; Bruce E Lewis
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.